This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Acclarent Launches A Complete Balloon Sinuplasty System For Children Who Suffer From Chronic Sinusitis

Acclarent, Inc. announced today the U.S. availability of the Relieva ® Spin Balloon Sinuplasty System with the M-110C Sinus Guide Catheter Tip designed to access small and tight sinus anatomy in children and adults. This innovation represents a new addition to Acclarent’s Balloon Sinuplasty portfolio, which physicians use to treat children who suffer from chronic maxillary sinusitis.

Balloon Sinuplasty Technology is a safe and minimally invasive system that widens the sinus openings of patients suffering from chronic sinusitis. This technology, used by ear, nose and throat (ENT) surgeons to treat patients with chronic sinusitis, has an excellent safety profile and is an effective treatment for blocked sinuses. 3,4,5,6,7

Sinusitis is one of the most common chronic health problems in the U.S., with 18 million office visits per year for chronic sinusitis. 1,2 Patients with chronic rhinosinusitis typically suffer from a combination of headaches, congestion, facial pain/pressure, and other symptoms impacting their physical, functional, and emotional quality of life. While chronic sinusitis is typically treated first with medication, at least 20 percent of patients do not respond adequately to such treatment. 8,9,10 For children suffering from this condition, it can result is considerable loss of school time and accumulation of medical expenses. 11

“As the leader in Balloon Sinuplasty technology, Acclarent is pleased to offer the Relieva ® Spin Balloon Sinuplasty System for children who suffer from chronic maxillary sinusitis,” said Dr. Howard Levine, otolaryngologist and Acclarent Vice President of Clinical and Medical Affairs. “Our Balloon technology has been used in over 300,000 adults and children who suffer from chronic sinusitis and this launch continues to support Acclarent’s mission to provide sinus relief to children as well.” 12

The Relieva ® Spin Balloon Sinuplasty System provides a means to access the sinus space and to dilate the sinus ostia and spaces associated with the paranasal sinus cavities for diagnostic and therapeutic procedures. For children aged 17 and under, Relieva ® Spin Balloon Sinuplasty System is intended to dilate sinus ostia and spaces associated with the maxillary sinus for diagnostic and therapeutic procedures. The new Relieva ® Spin M-110C sinus guide catheter tip is designed to work with the existing Relieva ® Spin Balloon Sinuplasty System portfolio, and to access small and tight anatomy.

“The Relieva ® Spin Balloon Sinuplasty System is a single-handed system to access and dilate sinus cavities and offers flexible over-the-wire technology,” said Dr. Eric Waki, pediatric otolaryngologist. “The product’s design allows me to effectively treat all different types of patients, including adults and children with small anatomy.”

About Acclarent, Inc.

Acclarent, Inc., a business unit of Johnson & Johnson, is a medical device company located in Menlo Park, CA. Its singular focus is to free patients to live better lives by designing, developing and commercializing medical devices that address conditions affecting the ear, nose, and throat (ENT). For more information, visit www.acclarent.com or www.BalloonSinuplasty.com.

Dr. Waki is compensated for his services as a member of the company’s Speakers Bureau and provides other consulting services.

1   Benninger, M. Adult chronic rhinosinusitis: Definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 2003;129S:S1-S32.

2

Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey, 2010. National Center for Health.
3 Bolger W, Brown CL, et al. Safety and outcomes of balloon catheter sinusotomy: a multicenter 24-week analysis in 115 patients. Otolaryngol Head Neck Surg. 2007;137(1):10-20.
4 Levine HL, Sertich AP, et al. Multicenter registry of balloon catheter sinusotomy outcomes for 1,036 patients. Ann Otol Rhinol Laryngol. 2008;117(4):263-270.
5 Karanfilov B, Silvers S, et al. Office-based balloon sinus dilation: a prospective, multicenter study of 203 patients. Int Forum Allergy Rhinol. 2012;Nov 7. doi:10.1002/alr.21112.
6 Ramadan HH, McLaughlin K, et al. Balloon Catheter Sinuplasty in Young Children. American Journal of Rhinologya nd Allergy, 2010; 24(1):e54-e56
7 Ramadan HH, Terrell AM. Balloon catheter sinuplasty and adenoidectomy in children with chronic rhinosinusitis. Annalys of Otology, Rhinology & Laryngology, 2010; 119(9):578-582.
8 Subramanian H, Schechtman, K. A Retrospective Analysis of Treatment Outcomes and Time to Relapse after Intensive Medical Treatment for Chronic Sinusitis. Am J Rhinol. 2002;16(6):303-312.
9 Hessler J, Piccirillo J, et al. Clinical outcomes of chronic rhinosinusitis in response to medical therapy: Results of a prospective study. Am J Rhinol. 2007;21(1):10-18.
10 Lal D, Scianna J, et al. Effi cacy of targeted medical therapy in chronic rhinosinusitis, and predictors of failure. Am J Rhinol Allergy. 23, 396-400, 2009.
11 Kay DJ, Rosenfeld RM. Quality of life for children with persistent sinonasal symptoms. Otolaryngol Head Neck Surg 2003;128:17- 26.
12 Acclarent Data on File, #10




1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs